315 related articles for article (PubMed ID: 26452336)
1. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.
Willemsen AE; Grutters JC; Gerritsen WR; van Erp NP; van Herpen CM; Tol J
Int J Cancer; 2016 May; 138(10):2312-21. PubMed ID: 26452336
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.
Min JH; Lee HY; Lim H; Ahn MJ; Park K; Chung MP; Lee KS
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1099-109. PubMed ID: 21913033
[TBL] [Abstract][Full Text] [Related]
3. Adverse events associated with mTOR inhibitors.
Pallet N; Legendre C
Expert Opin Drug Saf; 2013 Mar; 12(2):177-86. PubMed ID: 23252795
[TBL] [Abstract][Full Text] [Related]
4. Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials.
Zhang X; Ran YG; Wang KJ
Future Oncol; 2016 Jun; 12(12):1529-39. PubMed ID: 27067269
[TBL] [Abstract][Full Text] [Related]
5. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
Molas-Ferrer G; Soy-Muner D; Anglada-MartÃnez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
[TBL] [Abstract][Full Text] [Related]
6. [Molecular Mechanism-based Prediction of Interstitial Lung Disease Development Causedby Molecular Targeted Drugs: Association between Signal Transducer and Activator of Transcription 3 and Mammalian Target of Rapamycin inhibitor-induced Interstitial Lung Disease].
Yamamoto K
Yakugaku Zasshi; 2023; 143(11):911-916. PubMed ID: 37914338
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
[TBL] [Abstract][Full Text] [Related]
8. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.
Peddi PF; Shatsky RA; Hurvitz SA
Cancer Treat Rev; 2014 Mar; 40(2):320-6. PubMed ID: 24011786
[TBL] [Abstract][Full Text] [Related]
9. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
Hyldgaard C
Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.
Duran I; Goebell PJ; Papazisis K; Ravaud A; Weichhart T; Rodriguez-Portal JA; Budde K
Expert Opin Drug Saf; 2014 Mar; 13(3):361-72. PubMed ID: 24517115
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of mTOR in aging and cancer.
Zhavoronkov A
Oncotarget; 2015 Dec; 6(42):45010-1. PubMed ID: 26942715
[No Abstract] [Full Text] [Related]
13. Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient.
Tsubata Y; Hamada A; Sutani A; Isobe T
J Cancer Res Ther; 2012; 8(1):154-6. PubMed ID: 22531540
[TBL] [Abstract][Full Text] [Related]
14. The role of mTOR inhibitors in the management of posttransplant malignancy.
Monaco AP
Transplantation; 2009 Jan; 87(2):157-63. PubMed ID: 19155967
[TBL] [Abstract][Full Text] [Related]
15. [Rechallenge of everolimus for metastatic renal cell carcinoma after recovery from grade 3 interstitial lung disease: a case report].
Utsunomiya N; Kono Y; Matsumoto K; Matsumoto T; Nakagawa A; Tsunemori H; Okada T; Muguruma K; Kawakita M
Hinyokika Kiyo; 2014 Jan; 60(1):25-8. PubMed ID: 24594769
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.
Shah RR
Drug Saf; 2016 Nov; 39(11):1073-1091. PubMed ID: 27534751
[TBL] [Abstract][Full Text] [Related]
17. Risk of Metabolic Complications in Patients with Solid Tumors Treated with mTOR inhibitors: Meta-analysis.
Lew S; Chamberlain RS
Anticancer Res; 2016 Apr; 36(4):1711-8. PubMed ID: 27069150
[TBL] [Abstract][Full Text] [Related]
18. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
Yoneda KY; Shelton DK; Beckett LA; Gandara DR
J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
[TBL] [Abstract][Full Text] [Related]
19. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
[TBL] [Abstract][Full Text] [Related]
20. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]